This company is no longer active
Vascular Biogenics Balance Sheet Health
Financial Health criteria checks 6/6
Vascular Biogenics has a total shareholder equity of $19.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $24.6M and $5.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$24.26m |
| Equity | US$19.24m |
| Total liabilities | US$5.41m |
| Total assets | US$24.65m |
Recent financial health updates
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
May 18
Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?
Dec 24
Recent updates
VBL Therapeutics receives non-compliance letter from Nasdaq
Sep 01VBL Therapeutics GAAP EPS of -$0.12
Aug 15VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals
Jul 19Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
May 18Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump
Sep 03How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?
Mar 17How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?
Jan 28VBL Therapeutics expands the ovarian cancer trial in Europe
Dec 29Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?
Dec 24Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 19VBL Therapeutics EPS beats by $0.01, misses on revenue
Nov 16Financial Position Analysis
Short Term Liabilities: VBLT's short term assets ($24.5M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: VBLT's short term assets ($24.5M) exceed its long term liabilities ($108.0K).
Debt to Equity History and Analysis
Debt Level: VBLT is debt free.
Reducing Debt: VBLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VBLT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 15.7% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/17 01:52 |
| End of Day Share Price | 2023/10/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vascular Biogenics Ltd. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Alethia Young | Deutsche Bank |
| Etzer Darout | Guggenheim Securities, LLC |